4.3.3. Bipolar disorder and mania
For SPS Guidance on Lithium monitoring in Adults in Primary Care please click here
For Shared Care - Lithium Treatment Care Pathway (Lithium for patients with mania or hypomania, bipolar disorder or recurrent depression) Click Here
Please note: Patients must not be switched from the brand they were initiated on
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
MHRA 2018 guidance – Action required now from healthcare professionals
- Valproate medicines must not be used in women of childbearing potential unless the Pregnancy Prevention Programme is in place
- Provide the Patient Guide to the patient (or her parents or responsible person as necessary)
If you are involved in the care of female patients on valproate in the UK, see a reminder of actions required and how to order more patient guides for this medicine on the MHRA website
MHRA 2019 guidance - Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme.
For the above guidance Click Here
| Pack |
|---|
| 90 tablet |
| Pack |
|---|
| 90 tablet |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only